Bird&Be Raises $13M Series A for Fertility Wellness

Toronto-based Bird&Be has successfully closed a $13 million USD Series A funding round, injecting significant capital into its mission of enhancing reproductive wellness. The all-equity financing was co-led by the Business Development Bank of Canada's Thrive Fund and consumer-focused venture capital firm BFG Partners. This substantial investment underscores the growing investor confidence in the femtech sector, particularly in companies addressing critical aspects of fertility and reproductive health.

The company, which offers a suite of fertility and wellness supplements alongside diagnostic test kits, has experienced remarkable growth since its inception in 2019. Bird&Be reports achieving an "eight-figure brand" status with nearly 100% year-over-year revenue expansion, a testament to its effective direct-to-consumer model where approximately 75% of sales are driven by subscriptions. This financial infusion is earmarked to fuel further expansion and product development within the rapidly evolving North American fertility technology market.

Founded by Breanna Hughes and Samantha Diamond, both of whom have personal experiences with reproductive health challenges, Bird&Be aims to empower individuals by providing accessible tools for understanding and managing their fertility. The company's product line, which spans from prenatal to postpartum supplements, is designed to support individuals throughout their reproductive journey. All supplements are rigorously regulated by Health Canada under natural health product guidelines, ensuring quality and safety for consumers.

The Series A round also saw participation from notable investors including BAM Ventures, Founder Collective, Rejuvenation Ventures, and HSR Ventures. CEO Samantha Diamond confirmed that the funding round concluded in August and included a minor component of secondary share issuances. This broad investor support highlights a collective belief in Bird&Be's business model and its potential to capture a significant share of the growing reproductive health market.

Bird&Be's strategic focus on both male and female reproductive health is particularly relevant given global trends. The World Health Organization estimates that approximately one in six individuals worldwide face infertility issues. Furthermore, studies indicate a concerning decline in male fertility metrics over recent decades, a factor Bird&Be addresses by offering comprehensive testing and support for all genders. This inclusive approach positions the company favorably within a market increasingly recognizing the multifaceted nature of reproductive wellness.

The broader femtech industry continues to attract significant venture capital interest, with fertility and reproductive health technologies leading the charge in terms of investment dollars. Bird&Be's successful Series A positions it as a key player ready to capitalize on this momentum. The company's profitability and strong growth trajectory suggest a robust operational foundation, poised to leverage this new capital for sustained market penetration and innovation in reproductive care solutions.